On October 2, 2017, Opiant Pharmaceuticals, Inc., a Delaware corporation (“Opiant DE” or, after giving effect to the Reincorporation Merger (defined below), the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Opiant Pharmaceuticals, Inc., a Nevada corporation and then parent company of the Company (“Opiant NV”), to which Opiant NV would merge with and into Opiant DE for the sole purpose of reincorporating Opiant NV in the State of Delaware (the “Reincorporation Merger”). The Reincorporation Merger and the Merger Agreement were approved by the Board of Directors and sole stockholder of Opiant DE, and by the Board of Directors and a majority of stockholders of Opiant NV. The Reincorporation Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.

The description of the Merger Agreement set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which is filed by the Company as Exhibit 2.1 to this Form 8-K and incorporated herein by reference.

At 5:30 p.m. EST on October 2, 2017 (the “Effective Time”), Opiant DE and Opiant NV effected the Reincorporation Merger, thereby changing the state of incorporation of the Company from the State of Nevada to the State of Delaware to the Merger Agreement. The Reincorporation Merger was accomplished by the filing of (i) articles of merger with the Secretary of State of the State of Nevada (the “Nevada Articles of Merger”) and (ii) a certificate of merger (the “Delaware Certificate of Merger”) and the amended and restated certificate of incorporation of the Company (the “Amended and Restated Charter”) with the Secretary of State of the State of Delaware. to the Merger Agreement, the bylaws of Opiant DE are the bylaws of the Company following the Reincorporation Merger (the “Bylaws”). The description of the Nevada Articles of Merger, the Delaware Certificate of Merger, the Amended and Restated Charter and the Bylaws set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the Nevada Articles of Merger, the Delaware Certificate of Merger, the Amended and Restated Charter and the Bylaws attached as Exhibits 3(i).2, 3(i).3, 3(i).4 and 3(ii).1, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

Upon the Effective Time (i) Opiant NV merged with and into Opiant DE, (ii) the separate corporate existence of Opiant NV ceased to exist, (iii) Opiant DE (now the “Company”) is the surviving corporation of the Reincorporation Merger, (iv) each share of common stock of Opiant NV, $0.001 par value per share (the “NV Common Stock”), outstanding immediately prior to the Effective Time was converted into one fully-paid and non-assessable share of common stock of the Company, $0.001 par value per share (the “Common Stock”), and (v) in lieu of any fractional shares to which a holder of the Company’s Common Stock would have been entitled following the Effective Time, such fractional share was automatically rounded up to the next whole share. A specimen Common Stock certificate of Opiant DE is attached as Exhibit 4.1 to this Current Report on Form 8-K and incorporated herein by reference.

As a result of the Reincorporation Merger, the Company’s affairs ceased to be governed by the Nevada Revised Statutes, and became subject to the General Corporation Law of the State of Delaware. The Reincorporation Merger did not affect any of the Company’s material contracts with any third parties, and the Company’s rights and obligations under such material contractual arrangements continue to be rights and obligations of the Company after the Reincorporation Merger. The Reincorporation Merger also did not result in any change in headquarters, business, jobs, management, location of any of the offices or facilities, number of employees, benefit plans, assets, liabilities or net worth (other than as a result of the costs incident to the Reincorporation Merger) of the Company.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

The information set forth under Item 3.03 of this Current Report on Form 8-K is incorporated herein by reference.

Item 8.01 Other Events.

On October 2, 2017, immediately prior to the Effective Time of the Reincorporation Merger, and to approval of a majority of its stockholders, Opiant NV (i) reduced the total number of authorized shares of the NV Common Stock from 1,000,000,000 to 200,000,000, and (ii) established a classified board of directors.

The description of the Certificate of Amendment to the Articles of Incorporation set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment to the Articles of Incorporation attached as Exhibit 3(i).1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

OPIANT PHARMACEUTICALS, INC. Exhibit
EX-2.1 2 opnt-10032017xex21.htm EXHIBIT 2.1 Exhibit Exhibit 2.1AGREEMENT AND PLAN OF MERGERBETWEENOPIANT PHARMACEUTICALS,…
To view the full exhibit click here

About OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT)

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.